Adenosine deaminase deficiency in adults by Ozsahin, H et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 1997
Adenosine deaminase deficiency in adults
Ozsahin, H; Arredondo-Vega, F X; Santisteban, I; Fuhrer, H; Tuchschmid, P; Jochum,
W; Aguzzi, A; Lederman, H M; Fleischman, A; Winkelstein, J A; Seger, R A;
Hershfield, M S
Ozsahin, H; Arredondo-Vega, F X; Santisteban, I; Fuhrer, H; Tuchschmid, P; Jochum, W; Aguzzi, A; Lederman, H
M; Fleischman, A; Winkelstein, J A; Seger, R A; Hershfield, M S. Adenosine deaminase deficiency in adults.
Blood 1997, 89(8):2849-55.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Blood 1997, 89(8):2849-55.
Ozsahin, H; Arredondo-Vega, F X; Santisteban, I; Fuhrer, H; Tuchschmid, P; Jochum, W; Aguzzi, A; Lederman, H
M; Fleischman, A; Winkelstein, J A; Seger, R A; Hershfield, M S. Adenosine deaminase deficiency in adults.
Blood 1997, 89(8):2849-55.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Blood 1997, 89(8):2849-55.
Adenosine deaminase deficiency in adults
Abstract
Adenosine deaminase (ADA) deficiency typically causes severe combined immunodeficiency (SCID) in
infants. We report metabolic, immunologic, and genetic findings in two ADA-deficient adults with
distinct phenotypes. Patient no. 1 (39 years of age) had combined immunodeficiency. She had frequent
infections, lymphopenia, and recurrent hepatitis as a child but did relatively well in her second and third
decades. Then she developed chronic sinopulmonary infections, including tuberculosis, and
hepatobiliary disease; she died of viral leukoencephalopathy at 40 years of age. Patient no. 2, a healthy
28-year-old man with normal immune function, was identified after his niece died of SCID. Both
patients lacked erythrocyte ADA activity but had only modestly elevated deoxyadenosine nucleotides.
Both were heteroallelic for missense mutations: patient no. 1, G216R and P126Q (novel); patient no. 2,
R101Q and A215T. Three of these mutations eliminated ADA activity, but A215T reduced activity by
only 85%. Owing to a single nucleotide change in the middle of exon 7, A215T also appeared to induce
exon 7 skipping. ADA deficiency is treatable and should be considered in older patients with
unexplained lymphopenia and immune deficiency, who may also manifest autoimmunity or unexplained
hepatobiliary disease. Metabolic status and genotype may help in assessing prognosis of more mildly
affected patients.
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Adenosine deaminase (ADA) deficiency typically causes se- vated deoxyadenosine nucleotides. Both were heteroallelic
for missense mutations: patient no. 1, G216R and P126Qvere combined immunodeficiency (SCID) in infants. We re-
port metabolic, immunologic, and genetic findings in two (novel); patient no. 2, R101Q and A215T. Three of these mu-
tations eliminated ADA activity, but A215T reduced activityADA-deficient adults with distinct phenotypes. Patient no.
1 (39 years of age) had combined immunodeficiency. She by only 85%. Owing to a single nucleotide change in the
middle of exon 7, A215T also appeared to induce exon 7had frequent infections, lymphopenia, and recurrent hepati-
tis as a child but did relatively well in her second and third skipping. ADA deficiency is treatable and should be consid-
ered in older patients with unexplained lymphopenia anddecades. Then she developed chronic sinopulmonary infec-
tions, including tuberculosis, and hepatobiliary disease; she immune deficiency, who may also manifest autoimmunity
or unexplained hepatobiliary disease. Metabolic status anddied of viral leukoencephalopathy at 40 years of age. Patient
no. 2, a healthy 28-year-old man with normal immune func- genotype may help in assessing prognosis of more mildly
affected patients.tion, was identified after his niece died of SCID. Both patients
lacked erythrocyte ADA activity but had only modestly ele- q 1997 by The American Society of Hematology.
tion. She had been hospitalized eight times for pneumonitis in theD previous year. Her family history was unremarkable and included aEFICIENCY OF adenosine deaminase (ADA) typicallycauses Severe Combined Immune Deficiency (SCID)
healthy 13-year-old daughter. In early childhood she had eczematoidin infants, who present with growth failure, opportunistic
dermatitis and frequent febrile convulsions, otitis media, pneumoni-infections, lymphopenia, and defective cellular and humoral
tis, hepatitis, furunculosis, and diarrhea. At 5 years of age, perforat-immune function.1,2 Immunodeficiency results from toxic ef- ing appendicitis was complicated by abdominal wall necrosis; herfects of ADA substrates, including apoptosis induced by granulocyte count was 1,100/mL and her lymphocyte count was 900/deoxyadenosine triphosphate (dATP) pool expansion3-5 and mL. An extensive search, including spleen biopsy, failed to account
inhibition of transmethylation reactions caused by impaired for neutropenia, lymphopenia, thrombocytopenia, hepatitis, and sple-
catabolism of S-adenosylhomocysteine6-8 (reviewed in nomegaly.
Hershfield et al2). ADA0 SCID is treatable by marrow trans- Pulmonary infections were frequent until age 11; leukopenia per-
plantation and enzyme replacement; gene therapy trials are sisted. The patient then did fairly well until age 28, when she became
septic after cesarian section. A year later she developed hepatomeg-underway.
aly, cholecystitis, and cholelithiasis. Liver biopsy specimens showedAfter the discovery of ADA0 SCID in 1972, screening
granulomas of undetermined cause. She developed pancytopenia andprograms identified rare healthy children whose red blood
chronic sinopulmonary infections. Asthma and serum IgE of 1,780cells (RBCs) lacked ADA but whose nucleated cells had
International Units (IU)/mL (normal, 47 to 200 IU/mL) raised suspi-5% to 70% of normal activity (partial deficiency).9-13 More
cion of hyper-IgE syndrome. At age 30 she was treated for pulmo-
recently, ADA deficiency has been discovered in several
nary tuberculosis; at age 34 she underwent lobectomy for hemopty-
older children and in two sisters in their mid-30s with late sis. At age 38, computerized tomography (CT) showed diffuse
or adult onset of immunodeficiency.14-17 More than 40 mutant pulmonary miliary infiltrates with fibrosis and bronchiectasis, hepa-
ADA alleles have been identified.2,18 In SCID patients, nei- tosplenomegaly, and cholelithiasis.
ther allele encodes an active enzyme, whereas in more mildly Immunologic evaluation at age 39 showed a total lymphocyte
affected patients, at least one ADA gene product appears to count of 275/mL (CD4/ T lymphocytes, 190/mL; CD8/ T lympho-
cytes, 60/mL; and CD19/ B lymphocytes, 20/mL). Lymphoprolifera-have some function. The extent of deoxyadenosine (dAdo)
tive responses to mitogens were diminished (phytohemagglutinin,induced dATP accumulation and S-adenosylhomocysteine
34,051 disintigrations per minute (dpm); pokeweed mitogen, 10,917hydrolase inactivation in RBCs reflect the degree of ADA
deficiency.19-21
Whether some children with partial ADA deficiency pro- From the Division of Immunology/Hematology, University Chil-
gress to an immune deficient state is unclear. To date, ADA dren’s Hospital, Zurich, Switzerland; the Departments of Medicine
deficiency has been identified as a cause of adult-onset im- and Biochemistry, Duke University School of Medicine, Durham,
NC; the Department of Medicine. Triemli Hospital, Zurich Switzer-munodeficiency in only a single family.17 Because of atypical
land; the Neuropathology Institute of the University of Zurich, Swit-features, older patients may be misdiagnosed with a disease
zerland; and the Eudowood Division of Pediatric Immunology, Theof unknown cause, such as common variable immunodefi-
Johns Hopkins University School of Medicine, Baltimore, MD.ciency or idiopathic CD4/ T lymphocytopenia.22,23 To better
Submitted August 2, 1996; accepted November 25, 1996.define and increase awareness of the spectrum of manifesta-
Supported in part by grants from the National Institutes of Healthtions in adults, we report the metabolic, immunologic, and (DK20902) and from Enzon, Inc to M.S.H.genetic findings in two patients diagnosed with ADA defi- Address reprint requests to Michael S. Hershfield, MD, Box 3049,
ciency in adult life: one overtly immunodeficient and the Duke University Medical Center, Durham, NC 27710.
other still in good health. The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hereby markedMATERIALS AND METHODS
‘‘advertisement’’ in accordance with 18 U.S.C. section 1734 solely to
Study Subjects indicate this fact.
q 1997 by The American Society of Hematology.Patient no. 1. This cachectic 39-year-old woman was referred
to the University of Zurich pediatric clinic for immunologic evalua- 0006-4971/97/8908-0039$3.00/0
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Table 1. List of PCR Primers Single-Strand Conformational Polymorphism (SSCP)
Analysis1 (/) 5*TGCCAAGCTTAGCCGGCAGAGACCCACCGAG
2 (0) 5*CTAGGAATTCGCATGCCACCAGCCATGG The amplified genomic exon 5 product was subjected to nested3 (/) 5*CGCGCGAATTCATGGCCCAGACGCCCGCCTTCGAC
PCR of nt 25,861 to 26,031 with primer 9 (5* end-labeled with 32P-4 (0) 5*GCGCAAGCTTCAGAGGTTCTGCCCTGCAGAGGC
5 (/) 5*ATGCTGTTGAAGCAGGCAGCATGACTAGGA gdATP) and primer 10. The product was denatured and electropho-
6 (0) 5*TGCCTGCTTCCCAGGGTGTCGAAGAGATTT resed on a 0.51 MDETM gel containing 10% glycerol, followed
7 (/) 5*GCGGAAGCTTCAAAGCCTCCTCTTCCTC by autoradiography, as recommended by the gel manufacturer (AT8 (0) 5*GCGCGAATTCAGGTCTCCAGTTGTTTCATG
Biochem, Malvern, PA). For dideoxy sequencing, a separate nested9 (/) 5*CCCATCCCTACTCCT
10 (0) 5*CCCTGGGCAGGGCGG PCR product (nt 25,794 to 26,169) was generated using unlabeled
11 (0) 5*GGAATTCGAAGTGCATGTTTTCCTGCCGCAGCC primers 9 and 10.
12 (/) 5*CCAGACGAGGTGGTGGC
13 (0) 5*AGAAGCTCCCTCTTTTCATC
Screening cDNA Subclones for the R101Q Mutation and
Retention of Exon 7
cDNA nt 96 to 872 (ATG start codon through exon 8) was ampli-
fied with primers 3 and 11. Bsg I digestion then distinguished exondpm; and anti-CD3 34,947 dpm) and were absent to antigens (can-
4 wild type (resistant) from R101Q mutant clones (sensitive). cDNAdidin, diphtheria, cytomegalovirus, and tetanus). IgG measured 1
nt 471 to 1,126 (exons 5 to 11) was amplified using primers 12 andweek after an intravenous Ig infusion was normal at 14.7 g/L (IgG1,
13. Digestion with Nci I then distinguished clones containing exon12.0 g/L; IgG2, 0.61 g/L). IgA (1.05 g/L) and IgM (0.3 g/L) were
7 (sensitive) from those lacking exon 7 (resistant). The normal exonboth less than the 10th percentile. IgE was 1,232 IU/mL. No antibody
7 Nci I site is unaffected by the A215T mutation.response could be detected to pneumococcal polysaccharide, diph-
theria, or tetanus toxoids. Rheumatoid factor (RF), antinuclear anti-
body (ANA), antinative DNA, and Coombs’ tests were negative. Construction of ADA cDNA Containing the P126Q or
Human immunodeficiency virus was excluded by polymerase chain A215T Mutations
reaction (PCR). Because these findings pointed to combined T- and P1260 cDNA. Using recombinant PCR,28 two primary PCR reac-B-cell immunodeficiency, metabolic studies were performed, which
tions were performed with wild-type ADA cDNA as template andled to the diagnosis of ADA deficiency.
the primer pairs (mutation underlined): (1) P126Q (/), 5*GAA-Five months after diagnosis and while receiving corticosteroid GGGGACCTCACCCAAGACGA and primer 4; and (2) primer 3
therapy for chronic obstructive pulmonary disease, patient no. 1
and P126Q (0) 5*CCACCTCGTCTTGGGTGAGGT. The two PCRdeveloped gastrointestinal candidiasis and progressive hemiplegia. products (having a central 15-bp overlap) were gel purified, com-Brain CT and magnetic resonance imaging (MRI) studies showed bined, annealed, and amplified with primers 3 and 4. The final prod-
the evolution over several weeks of multiple hypodense ischemic
uct was gel purified, cut with EcoRI/HindIII, and cloned into pBlue-foci and central pontine myelinosis. Brain biopsy specimens estab-
script (Stratagene, La Jolla, CA). Sequencing identified the P126Qlished the diagnosis of progressive multifocal leukoencephalopathy
mutation and no other change.
caused by JC virus. She died after developing tetraplegia and bulbar A215T cDNA. Primers for the primary reactions were (1) primerparalysis. 2 and A215T (/) 5*ACTGTCCACACCGGGGAGGT; and (2)Patient no. 2. This 28-year-old man was found to lack erythro- primer 1 and A215T (0) 5*CCTCCCCGGTGTGGACAG. The prod-
cyte ADA activity while screening the family of his infant niece,
ucts were purified, annealed, extended, amplified with primers 1 and
who had died after a haploidentical bone marrow transplant for 2, cut with EcoRI/HindIII, and cloned into pBluescript. SequencingADA0 SCID. His past history was unremarkable except for recurrent
showed the A215T mutation and no other change.
tonsillitis beginning at age 10 years, which ceased after a tonsillec-
tomy at age 23. He had no history of recurrent otitis, bronchitis, Effect of Mutations on ADA Catalytic Activitypneumonia, sepsis, meningitis, or hepatitis.
As reported,16,27,29 mRNA transcribed in vitro from wild-type andHematologic and immunologic evaluation showed a white blood
mutant ADA cDNA subclones was translated in a rabbit reticulocytecell (WBC) count of 5,700/mL with 25% lymphocytes (1,420/mL),
lysate in the presence of [35S]methionine. Aliquots containing equal66% neutrophils, 5% monocytes, 3% eosinophils, and 1% basophils.
amounts of wild-type and mutant translation products (shown byHe had 82.9% CD3/ T cells, 64.7% CD4/ T cells (906/mL), and
10% sodium dodecyl sulfate-mercaptoethanol polyacrylamide gel17.4% CD8/ T cells (CD4/CD8 ratio, 3.72). Serum IgG was 708
electrophoresis and fluorography) were electrophoresed on cellulosemg/dL, IgA was 246 mg/dL, and IgM was 65 mg/dL. He had protec-
acetate and stained for ADA activity in situ.tive levels of serum antibody to rubella, rubeola, mumps, tetanus,
and Haemophilus influenzae type b. Lymphoproliferative responses
to mitogens, tetanus toxoids, and allogeneic cells were normal. RESULTS
Patient No. 1 (CKu) and Family
Mutational Analysis In RBC of patient no. 1, ADA activity was 0.2 nmol/h/
ADA cDNA and genomic sequences are as reported.24,25 General mg protein (normal { 1 standard deviation [SD], 80.4 {
PCR methods for amplifying ADA genomic and cDNA segments 40.2); S-adenosylhomocysteine hydrolase activity was 0.59
(the latter numbered from the start of transcription, with translation nmol/h/mg (normal, 4.2 { 1.9); and total deoxyadenosine
starting at position 96) and for cloning and sequencing PCR products
nucleotides (dAXP) were 28 nmol/mL (normal, 2). Blood
are as described.16,26,27 Specific target sequences amplified for this
mononuclear cells were not available for analysis.
study included (primers listed in Table 1): cDNA nucleotide (nt) 16
BstXI digestion of exon 7 amplified from genomic DNAto 1,497 (full length), primers 1 and 2; cDNA nt 96 to 1,188 (coding
of patient no. 1 indicated heterozygosity for the mutation,region), primers 3 and 4; genomic exon 7 (nt 28,376 to 29,115
codon 216 GGGGlycine to AGGArginine (G216R) (data notspanning introns 6 to 9), primers 5 and 6; and genomic exon 5 (nt
25,794 to 26,169), primers 7 and 8. shown), which occurs in 10% to 15% of ADA-deficient pa-
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Fig 1. Analysis of ADA genotype of patient no. 1 and family. (A)
SSCP analysis of genomic exon 5. Lanes 1 and 2, controls; lane 3,
patient no. 1. (B) Sequencing gel showing heterozygosity of patient
no. 1 for the P126Q mutation in genomic exon 5 DNA. (C) Pedigree
of family 1. Arrow indicates patient no. 1 (II-1).
tients16,30 (and unpublished data). SSCP analysis suggested P126Q from her father; she transmitted P126Q to her daugh-
ter (data not shown, Fig 1C).that her second ADA allele had a mutation in exon 5 (Fig
1A). Sequencing of amplified genomic exon 5 showed heter-
Patient No. 2 and Familyozygosity for a C  A transversion of genomic nt 25902
(mRNA nt 472; Fig 1B). This mutation, codon 126 CCAProline In the SCID proband (III-1, Fig 2A), RBC ADA was 0.1
to CAAGlutamine (P126Q), has not been previously reported. nmol/h/mg protein, and dAXP were 508 nmol/mL. These
values for patient no. 2, her healthy maternal uncle (II-3,Patient no. 1 had inherited G216R from her mother and
AID Blood 0054 / 5h33$$1062 03-11-97 23:24:17 blda WBS: Blood
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Fig 2. Analysis of ADA cDNA and genomic DNA of patient no. 2
and family. (A) Pedigree of family 2. Arrow indicates patient no. 2 (II-
3); † indicates the deceased proband (III-1), an infant with SCID whose
genotype is presumed. (B) Sequence of genomic exon 7 DNA (patient
no. 2, left; control, right). Patient no. 2 is heterozygous for the A215T
mutation. (C) Ethidium-stained agarose gel illustrating the method
of screening cDNA clones for the R101Q mutation and for retention
of exon 7 (see the Materials and Methods). Numbers at right indicate
length in nucleotides of DNA markers. Lanes 1 and 2, PCR fragments
(exons 1 to 8) digested with Bsg I. Lane 1, clone bearing R101Q
mutation (cuts with Bsg I); lane 2, clone with wild-type (R101) exon
4 (lacks Bsg I site). Lanes 3 and 4, PCR fragments (exons 5 to 11)
digested with Nci I. Lane 3, clone containing exon 7 (cuts with Nci I
within exon 7); lane 4, clone with a deletion of exon 7 (lacks exon 7
Nci I site).
Fig 2A), were 0.1 nmol/h/mg and 15 nmol/ml, respec- family members indicated that patient no. 2 had inherited
tively. All other family members studied had normal or het- A215T maternally and R101Q paternally (Fig 2A). His sister
erozygous range ADA activity and undetectable dAXP. had inherited a wild-type allele and R101Q, and her husband
ADA activity in cultured T cells from patient no. 2 was 170 was heterozygous for G216R; they had presumably transmit-
nmol/h/mg protein versus 1,435 and 1,918 for T cells of his ted R101Q and G216R alleles to their ADA0 SCID daughter
sister and her husband, the parents of the SCID proband (who was not studied; Fig 2A).
(normal, 2,047 { 1,36016). Our initial analysis of cDNA from patient no. 2 suggested
Five ADA cDNA subclones from T cells of patient no. an allele-specific skipping of exon 7. To assess this further,
2 had a previously reported exon 4 mutation, codon 101 we screened a second random group of cDNA clones from
CGGArginine to CAGGlutamine (R101Q).31 Amplified genomic his T cells (Fig 2C). Overall, of 32 clones analyzed, 4 of 8
DNA was heterozygous for a Bsg I site created by R101Q. (50%) A215T-derived clones lacked exon 7, compared with
Three cDNA subclones lacking this Bsg I site had a deletion 3 of 24 (12.5%) bearing the R101Q mutation (similar to the
of exon 7, but no other mutation, suggesting that his second 10% to 15% frequency of exon 7 skipping in normal cells31).
allele might have a deletion or splice site mutation of exon In a previous report of a child homozygous for A215T, only
7. Sequencing of his amplified genomic DNA showed nor- four cDNA clones were sequenced, but one lacked exon 7
mal exon 7 splice junctions, but heterozygosity for a pre- and another had missplicing of intron 6.13 Our data on a
viously reported exon 7 missense mutation, codon 215 larger number of cDNA clones from a heteroallelic patient
more clearly indicate that A215T is associated with bothGCCAlanine to ACCThreonine (A215T; Fig 2B).13 Analysis of
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basis. Thus, hepatocellular degeneration is fatal in newborn
ADA knockout mice,35,36 and we have reported a child with
ADA0 SCID who presented with persistent neonatal hepati-
tis, apparently without infectious cause, which resolved rap-
idly with enzyme replacement.37
Both mutations of patient no. 1, G216R and P126Q,
greatly reduced ADA activity. However, her RBC dAXP
level (28 nmol/mL) was lower than has been reported for
immunodeficient patients (350 to 1,800 nmol/mL for
SCID; 60 to 300 nmol/mL for those with a later on-
set16,26,38,39). This may reflect a hypoplastic marrow, because
RBC dAdo (precursor of dAXP) arises from DNA degraded
during normal marrow cell turnover.40,41 However, modestFig 3. In situ stain for ADA activity of in vitro translation products.
dAXP elevation may reflect greater residual ADA activityArrow indicates position of human ADA. The dark bands at the bot-
tom and top are rabbit hemoglobin and rabbit ADA, respectively, in vivo than suggested from cDNA expression. G216R prob-
carried over from the reticulocyte translation reaction. The transla- ably eliminates activity irreversibly by interacting with the
tion reactions were primed with the normal (wild-type) or mutant
active site residue glutamate 21742; it is always associated
human ADA mRNAs (transcribed from cDNA); lane 1, wild-type con-
with SCID when homozygous or combined with anothertrol; lane 2, blank; lane 3, A215T (patient no. 2); lane 4, R101Q (patient
severe allele (Hirschhorn et al30 and unpublished data). How-no. 2); lane 5, P126Q (patient no. 1); lane 6, G216R (patient no. 1);
lane 7, wild-type control. ever, P126Q occurs in a helical segment that has no contact
with the active site; this protein might be stabilized or in-
duced to fold properly in lymphoid cells, which normally
express very high ADA activity (as discussed elsewhere43).increased loss of exon 7 and a relative decrease in transcript
Another phenomenon that should be considered is somaticlevel. Two other exon 7 missense mutations (G216R and
mosaicism, which was recently found in two ADA-deficientR211H) did not appear to have such effects16,27 (and F.X.
patients who were immunodeficient as children, but then,A.-V., I.S., M.S.H., unpublished data, Duke University).
like patient no. 1, had remissions lasting at least into their
second decade.44,45 Selective survival of ADA/ lymphocytesActivity of Expressed Mutant ADA Alleles
was postulated to explain their low RBC dAXP levels and
The A215T in vitro translation product was 10% to 20% improved immune function. Tissues from patient no. 1 were
as active as the wild type; the newly identified P126Q mutant not available for study. However, her clinical improvement,
protein was inactive, as were the R101Q and G216R proteins although prolonged, was not sustained. If present, mosaicism
(Fig 3). We have also expressed these cDNAs in Escherichia may not have occurred in a stem cell, and thus might have
coli Sø3834 (an ADA deletion strain32). A215T had approxi- been unstable.
mately 15% of wild-type ADA activity, compared with ap- The A215T allele, discovered in a healthy child with par-
proximately 0.1% for P126Q and R101Q and less than 0.01% tial ADA deficiency,13 can plausibly explain the benign status
for G216R (F.X.A., I.S., M.S.H., study in progress). Because of patient no. 2 at age 28. A215T cDNA-encoded protein
exon 7 skipping eliminates activity,33 the loss of ADA activ- had 10% to 15% of wild-type activity, 100-fold more than
ity owing to the A215T mutation may be greater than is his R101Q cDNA product (the SCID phenotype and high
evident from the expressed cDNA, which reflects only the RBC dAXP of the niece of patient no. 2 is consistent with
effect of the amino acid substitution. R101Q being a null mutation). Significant in vivo ADA
function in patient no. 2 is indicated by activity in lysates
DISCUSSION of his T cells and by RBC dAXP in a range (¡20 nmol/
mL) found in healthy individuals with partial ADA defi-Lymphopenia and immune deficiency were appreciated in
ciency.20,29,46,47 We plan to monitor dAXP yearly for correla-patient no. 1 at age 5, but ADA deficiency was then unknown
tion with immunologic and clinical status.and only aggressive treatment of infections could be offered.
The mechanism by which A215T alters exon 7 processingRemarkably, she survived and did relatively well from pu-
(apparently enhancing an effect that occurs with normalberty until age 28, when she began to have serious respiratory
ADA pre-mRNA31) is unclear. The mutation occurs at nt 37/infections, including tuberculosis. She developed chronic
72 of exon 7, distant from splice junctions, and it does notpulmonary and hepatobiliary insufficiency and at 40, fatal
create a new splice site. Some midexonic nonsense mutationsleukoencephalopathy caused by JC papovavirus, a disorder
can, through unclear mechanisms, induce exon skipping andprevalent in the acquired immunodeficiency syndrome
reduce mRNA abundance,48,49 eg, the R142X mutation at nt(AIDS).34 This history suggests that cellular and humoral
62/116 of ADA exon 5.29 Skipping of exon 7 maintainsimmune dysfunction were not initially as complete as in
reading frame, so A215T does not induce a secondary non-SCID, which if uncorrected is fatal by age 1 to 2 years, but
sense codon. Further study of the effects of A215T on splic-decreased to critical levels in the fourth decade, presumably
ing are warranted.owing to ongoing exposure to toxic metabolites. We wish
ADA deficiency is treatable, but the longer diagnosis isto speculate that unexplained episodes of hepatitis from
childhood in patient no. 1 may also have had a metabolic delayed, the less reversible are its chronic consequences.
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and protein turnover for the enzyme variants in human B-Because of her age and clinical status, patient no. 1 was
lymphoblast cell lines. J Biol Chem 260:3875, 1985not a candidate for marrow transplantation. Local regulatory
11. Hirschhorn R, Ellenbogen A: Genetic heterogeneity in adeno-issues prevented access to polyethylene glycol-modified
sine deaminase (ADA) deficiency: Five different mutations in fiveADA (approved as an ‘‘Orphan Drug’’ in the United States
new patients with partial ADA deficiency. Am J Hum Genet 38:13,
and used in eight other countries for treating ADA defi- 1986
ciency50-52). Earlier diagnosis would have enhanced the 12. Hirschhorn R, Tzall S, Ellenbogen A, Orkin SH: Identification
chance of benefiting from either therapy and might have of a point mutation resulting in a heat-labile adenosine deaminase
prompted avoidance of glucocorticoids, which were also (ADA) in two unrelated children with partial ADA deficiency. J
used extensively before diagnosis of ADA deficiency in the Clin Invest 83:497, 1989
13. Hirschhorn R, Tzall S, Ellenbogen A: Hot spot mutations inadult sisters reported previously.38
adenosine deaminase deficiency. Proc Natl Acad Sci USA 87:6171,There are no strict immunological parameters for identi-
1990fying older ADA-deficient patients. Opportunistic infections
14. Geffner ME, Stiehm ER, Stephure D, Cowan MJ: Probablemay play a less prominent role than in patients with early
autoimmune thyroid disease and combined immunodeficiency dis-onset, and older patients have manifested asthma, autoimmu-
ease. Am J Dis Child 140:1194, 1986
nity, and signs of immune dysregulation, eg, IgG subclass 15. Levy Y, Hershfield MS, Fernandez-Mejia C, Polmar SH, Scu-deficiency or elevated serum IgE.15,16,38,39 The diagnosis diery D, Berger M, Sorensen RU: Adenosine deaminase deficiency
should be considered in adults with persistent lymphopenia with late onset of recurrent infections: Response to treatment with
and immunodeficiency of unknown cause (eg, some cases polyethylene glycol-modified adenosine deaminase (PEG-ADA). J
of common variable immune deficiency). Once ADA defi- Pediatr 113:312, 1988
16. Santisteban I, Arredondo-Vega FX, Kelly S, Mary A, Fischerciency is diagnosed, metabolite and genotype analysis may
A, Hummell DS, Lawton A, Sorensen RU, Stiehm ER, Uribe L,help in assessing prognosis and in providing genetic counsel-
Weinberg K, Hershfield MS: Novel splicing, missense, and deletioning.
mutations in 7 adenosine deaminase deficient patients with late/
delayed onset of combined immunodeficiency disease: Contribution
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